Dihexa: A Research Overview

Dihexa is one of the most striking — and most cautionary — compounds in this library. It has been described in preclinical reports as dramatically more potent than BDNF at building new synapses, which has made it a celebrated and controversial name in nootropic research. But three facts must sit at the front of any honest overview: the human evidence is nonexistent, the foundational papers linking it to its proposed mechanism were retracted in 2025, and the pathway it targets has a serious oncological dimension. The science is genuinely interesting; the appropriate caution is high, and the recent retractions make that doubly true.

This overview summarizes what the published literature reports about Dihexa — its identity, proposed mechanism, the state (and recent disruption) of the evidence, the safety considerations, and status. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Dihexa Is

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small synthetic peptide/peptidomimetic derived from angiotensin IV (Ang IV), a fragment of the renin-angiotensin system with known memory-related effects in rodents but poor stability and blood-brain-barrier penetration. Dihexa was engineered at Washington State University (the Harding lab) with modifications that increase stability and brain penetration (Dihexa origin and Ang IV derivation). It has a notably long half-life (reported around 12 days), which is itself a safety-relevant feature — effects cannot be quickly reversed.

Proposed Mechanism — HGF/c-Met and Synaptogenesis

The dominant proposed mechanism is that Dihexa acts on the hepatocyte growth factor (HGF)/c-Met receptor system in the brain — binding HGF and potentiating c-Met signaling — rather than acting solely through the canonical Ang IV (AT4/IRAP) target. Through this pathway, it is proposed to drive synaptogenesis, the formation of new synaptic connections underlying learning and memory (proposed HGF/c-Met synaptogenesis mechanism). An essential caveat regarding this mechanism: the key foundational papers proposing the HGF/c-Met dependence (Benoist/Kawas and a related 2012 paper) were formally retracted in April 2025 following an investigation into image manipulation, which substantially weakens the direct biochemical evidence linking Dihexa to HGF/c-Met (2025 retraction of foundational mechanism papers). The mechanism should therefore be described as proposed and now under a cloud, not established.

The Evidence Base — Preclinical Only, and Disrupted

All published Dihexa cognition data come from rodent and cell/zebrafish models — for example, restoration of cognitive performance in scopolamine-treated and aged rats, with reported synaptogenesis at very low concentrations; notably, it did not improve cognition in rats with already-normal cognition (preclinical-only cognitive findings). There are no published human efficacy trials for Dihexa itself (no human trials; research-only status). (A separate prodrug derivative, fosgonimeton/ATH-1017, was developed and tested in FDA-regulated trials, but that is a different compound from research-grade Dihexa.) Combined with the 2025 retractions, the honest summary is that there are striking preclinical claims, no human data, and a foundational evidence base that has been partly retracted.

• Angiotensin IV-derived peptidomimetic; long (~12-day) half-life; engineered for brain penetration.
• Proposed to drive synaptogenesis via HGF/c-Met — but the foundational mechanism papers were retracted in 2025.
• Evidence is preclinical only; no human efficacy trials for Dihexa itself; not approved.

Safety — The c-Met / Cancer Consideration

Dihexa’s safety considerations are serious and follow from its target. The c-Met receptor has a dual reputation: trophic and pro-regenerative in the nervous system, but a well-known oncogene driver in cancer biology (MET oncogene in cancer invasive growth, Front Pharmacol 2012). Activating or potentiating c-Met, therefore, raises a theoretical concern about promoting tumor growth, explicitly noted in the Dihexa literature (c-Met oncogenic / tumorigenesis theoretical risk). On top of this, no studies have examined Dihexa’s long-term safety in animals or humans, and its long half-life means exposure persists. This combination — a growth-pathway target with oncogenic potential, no long-term safety data, a long half-life, and retracted foundational evidence — places Dihexa firmly in a high-caution category.

Regulatory Status

The status below reflects mid-2026 and may change; verify before relying on it. Dihexa is not FDA-approved for any indication. It is sold as a research chemical for laboratory use only and, by its labeling, is not for human consumption; some clinics nonetheless use it off-label in a regulatory gray area. Its prodrug derivative being in formal clinical trials does not confer any approval on research-grade Dihexa.

Why Dihexa Draws Research Interest

Dihexa is a high-profile probe of growth-factor-driven synaptogenesis and a notable attempt to turn angiotensin-IV cognitive biology into a stable, brain-penetrant molecule. The accurate framing is a mechanistically intriguing but preclinical-only compound whose foundational mechanism evidence was partly retracted in 2025, with a serious c-Met/oncogenic safety consideration, no human data, no long-term safety data, and no approval — a compound that warrants substantial caution rather than enthusiasm.

For deeper reading, the cited sources are the best starting point. For other neurological research peptides, see the Semax and Selank overviews. The wider class is collected in our peptide research library.